We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · February 02, 2020

Transcatheter ViV vs Redo Surgical AVR for the Management of Failed Biological Prosthesis

JACC: Cardiovascular Interventions


Additional Info

JACC: Cardiovascular Interventions
Transcatheter ViV Versus Redo Surgical AVR for the Management of Failed Biological Prosthesis: Early and Late Outcomes in a Propensity-Matched Cohort
JACC Cardiovasc Interv 2020 Jan 15;[EPub Ahead of Print], DY Tam, C Dharma, RV Rocha, et al

Further Reading